Functional Validation of Single Domain Antibody-Derived CD33 Specific CAR-T Cells for the Treatment of Acute Myeloid Leukemia
Publications
Multiplex deletion of myeloid antigens by base editing in human hematopoietic stem and progenitor cells (HSPCs) enables potential for next generation transplant for acute myeloid leukemia (AML) treatment
Efficient knockout of both CD33 and CLL-1 by multiplex genome editing of human hematopoietic stem cells enhances the potential of next- generation transplants for acute myeloid leukemia (AML) treatment
Automated Closed Cell Processing System De-Risks Gene-Edited CD34+ Hematopoietic Stem Cell Manufacturing
TransACT enhances detection and characterization of translocation events from high-throughput sequencing data at base-pair resolution for gene editing products
Multiplex Deletion of Myeloid Antigens CD33 and CLL-1 by CRISPR/Cas9 in Human Hematopoietic Stem Cells Highlights the Potential of Next-Generation Transplantation for AML Treatment
A Novel Scalable Electroporation Platform for the Manufacturing of Gene Modified Hematopoietic Stem and Progenitor Cell Therapies
Novel Automated, Functionally Closed System for Rapid Immunomagnetic Negative Selection of T Cells
Multiplex Editing of Hematopoietic Stem and Progenitor Cells (HSPCs) with CRISPR Cas Nucleases Achieves High On Target Editing with Undetectable Translocations